Literature DB >> 28100402

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.

Roberta L Keller1, Eric C Eichenwald2, Anna Maria Hibbs3, Elizabeth E Rogers4, Katherine C Wai5, Dennis M Black6, Philip L Ballard4, Jeanette M Asselin7, William E Truog8, Jeffrey D Merrill7, Mark C Mammel9, Robin H Steinhorn10, Rita M Ryan11, David J Durand7, Catherine M Bendel12, Ellen M Bendel-Stenzel9, Sherry E Courtney13, Ramasubbareddy Dhanireddy14, Mark L Hudak15, Frances R Koch11, Dennis E Mayock16, Victor J McKay17, Jennifer Helderman18, Nicolas F Porta19, Rajan Wadhawan20, Lisa Palermo6, Roberta A Ballard4.   

Abstract

OBJECTIVE: To determine the effects of late surfactant on respiratory outcomes determined at 1-year corrected age in the Trial of Late Surfactant (TOLSURF), which randomized newborns of extremely low gestational age (≤28 weeks' gestational age) ventilated at 7-14 days to late surfactant and inhaled nitric oxide vs inhaled nitric oxide-alone (control). STUDY
DESIGN: Caregivers were surveyed in a double-blinded manner at 3, 6, 9, and 12 months' corrected age to collect information on respiratory resource use (infant medication use, home support, and hospitalization). Infants were classified for composite outcomes of pulmonary morbidity (no PM, determined in infants with no reported respiratory resource use) and persistent PM (determined in infants with any resource use in ≥3 surveys).
RESULTS: Infants (n = 450, late surfactant n = 217, control n = 233) were 25.3 ± 1.2 weeks' gestation and 713 ± 164 g at birth. In the late surfactant group, fewer infants received home respiratory support than in the control group (35.8% vs 52.9%, relative benefit [RB] 1.28 [95% CI 1.07-1.55]). There was no benefit of late surfactant for No PM vs PM (RB 1.27; 95% CI 0.89-1.81) or no persistent PM vs persistent PM (RB 1.01; 95% CI 0.87-1.17). After adjustment for imbalances in baseline characteristics, relative benefit of late surfactant treatment increased: RB 1.40 (95% CI 0.89-1.80) for no PM and RB 1.24 (95% CI 1.08-1.42) for no persistent PM.
CONCLUSION: Treatment of newborns of extremely low gestational age with late surfactant in combination with inhaled nitric oxide decreased use of home respiratory support and may decrease persistent pulmonary morbidity. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01022580.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bronchopulmonary dysplasia; prematurity; pulmonary morbidity; wheeze

Mesh:

Substances:

Year:  2017        PMID: 28100402      PMCID: PMC5367937          DOI: 10.1016/j.jpeds.2016.12.059

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  38 in total

1.  Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991-1992.

Authors:  Lex W Doyle
Journal:  Pediatr Pulmonol       Date:  2006-06

2.  Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.

Authors:  Richard A Ehrenkranz; Michele C Walsh; Betty R Vohr; Alan H Jobe; Linda L Wright; Avroy A Fanaroff; Lisa A Wrage; Kenneth Poole
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

3.  Inhaled nitric oxide in preterm infants--correction.

Authors:  Roberta A Ballard
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

4.  Perinatal risk-indicators for long-term respiratory morbidity among preterm or very low birth weight neonates.

Authors:  Margreet J Teune; Aleid G van Wassenaer; Stef van Buuren; Ben Willem J Mol; Brent C Opmeer
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2012-05-11       Impact factor: 2.435

5.  Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.

Authors:  Roberta A Ballard; William E Truog; Avital Cnaan; Richard J Martin; Philip L Ballard; Jeffrey D Merrill; Michele C Walsh; David J Durand; Dennis E Mayock; Eric C Eichenwald; Donald R Null; Mark L Hudak; Asha R Puri; Sergio G Golombek; Sherry E Courtney; Dan L Stewart; Stephen E Welty; Roderic H Phibbs; Anna Maria Hibbs; Xianqun Luan; Sandra R Wadlinger; Jeanette M Asselin; Christine E Coburn
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

6.  Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study.

Authors:  Debra A Stern; Wayne J Morgan; Anne L Wright; Stefano Guerra; Fernando D Martinez
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

7.  Prematurity and respiratory outcomes program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States.

Authors:  Gloria S Pryhuber; Nathalie L Maitre; Roberta A Ballard; Denise Cifelli; Stephanie D Davis; Jonas H Ellenberg; James M Greenberg; James Kemp; Thomas J Mariani; Howard Panitch; Clement Ren; Pamela Shaw; Lynn M Taussig; Aaron Hamvas
Journal:  BMC Pediatr       Date:  2015-04-10       Impact factor: 2.125

8.  Respiratory outcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT).

Authors:  Timothy P Stevens; Neil N Finer; Waldemar A Carlo; Peter G Szilagyi; Dale L Phelps; Michele C Walsh; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Jamie E Newman; Abhik Das; Barbara T Do; Kurt Schibler; Wade Rich; Nancy S Newman; Richard A Ehrenkranz; Myriam Peralta-Carcelen; Betty R Vohr; Deanne E Wilson-Costello; Kimberly Yolton; Roy J Heyne; Patricia W Evans; Yvonne E Vaucher; Ira Adams-Chapman; Elisabeth C McGowan; Anna Bodnar; Athina Pappas; Susan R Hintz; Michael J Acarregui; Janell Fuller; Ricki F Goldstein; Charles R Bauer; T Michael O'Shea; Gary J Myers; Rosemary D Higgins
Journal:  J Pediatr       Date:  2014-04-13       Impact factor: 4.406

9.  Diuretic exposure in premature infants from 1997 to 2011.

Authors:  Matthew M Laughon; Kim Chantala; Sofia Aliaga; Amy H Herring; Christoph P Hornik; Rachel Hughes; Reese H Clark; P Brian Smith
Journal:  Am J Perinatol       Date:  2014-05-06       Impact factor: 3.079

Review 10.  Preterm birth and childhood wheezing disorders: a systematic review and meta-analysis.

Authors:  Jasper V Been; Marlies J Lugtenberg; Eline Smets; Constant P van Schayck; Boris W Kramer; Monique Mommers; Aziz Sheikh
Journal:  PLoS Med       Date:  2014-01-28       Impact factor: 11.069

View more
  5 in total

1.  Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial.

Authors:  Katherine C Wai; Anna M Hibbs; Martina A Steurer; Dennis M Black; Jeanette M Asselin; Eric C Eichenwald; Philip L Ballard; Roberta A Ballard; Roberta L Keller
Journal:  J Pediatr       Date:  2018-04-04       Impact factor: 4.406

Review 2.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

3.  Composition and origin of lung fluid proteome in premature infants and relationship to respiratory outcome.

Authors:  Philip L Ballard; Juan Oses-Prieto; Cheryl Chapin; Mark R Segal; Roberta A Ballard; Alma L Burlingame
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

Review 4.  Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Authors:  Rishika P Sakaria; Ramasubbareddy Dhanireddy
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

5.  Comparative efficacy and safety of late surfactant preparations: a retrospective study.

Authors:  Morgan D Lane; Sujata Kishnani; Obianuju Udemadu; Samuel Eshun Danquah; Robert M Treadway; Aaliyah Langman; Stephen Balevic; Wesley M Jackson; Matthew Laughon; Christoph P Hornik; Rachel G Greenberg; Reese H Clark; Kanecia O Zimmerman
Journal:  J Perinatol       Date:  2021-07-20       Impact factor: 3.225

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.